SKBSY vs. PFE

Last updated Apr 2, 2026

Compare and contrast key facts about Skanska AB ser. B ADR (SKBSY) and Pfizer Inc. (PFE).

Performance

SKBSY vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Skanska AB ser. B ADR (SKBSY) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

SKBSY vs. PFE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SKBSY Skanska AB ser. B ADR	2.34%	41.62%	19.14%	19.90%	-36.16%	3.94%	20.80%	56.04%	-19.03%	-6.65%
PFE Pfizer Inc.	16.58%	0.65%	-2.22%	-41.26%	-10.41%	66.70%	3.07%	-6.91%	24.82%	15.90%

Fundamentals

Market Cap SKBSY : $11.63B PFE : $162.34B
EPS SKBSY : $13.73 PFE : $1.36
PE Ratio SKBSY : 2.04 PFE : 20.95
PS Ratio SKBSY : 0.07 PFE : 2.60
PB Ratio SKBSY : 0.19 PFE : 1.74
Total Revenue (TTM) SKBSY : $166.06B PFE : $62.58B
Gross Profit (TTM) SKBSY : $14.75B PFE : $44.01B
EBITDA (TTM) SKBSY : $7.63B PFE : $15.10B

Returns By Period

In the year-to-date period, SKBSY achieves a 2.34% return, which is significantly lower than PFE's 16.58% return. Over the past 10 years, SKBSY has outperformed PFE with an annualized return of 8.39%, while PFE has yielded a comparatively lower 4.49% annualized return.

SKBSY

• 1D: 1.49%
• 1M: -7.10%
• YTD: 2.34%
• 6M: 6.54%
• 1Y: 35.76%
• 3Y*: 26.89%
• 5Y*: 5.84%
• 10Y*: 8.39%

PFE

• 1D: 1.67%
• 1M: 4.73%
• YTD: 16.58%
• 6M: 8.56%
• 1Y: 24.79%
• 3Y*: -5.70%
• 5Y*: 0.19%
• 10Y*: 4.49%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SKBSY vs. PFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SKBSY

SKBSY Risk / Return Rank: 75
SKBSY Sharpe Ratio Rank: 77
SKBSY Sortino Ratio Rank: 72
SKBSY Omega Ratio Rank: 69
SKBSY Calmar Ratio Rank: 76
SKBSY Martin Ratio Rank: 80

PFE

PFE Risk / Return Rank: 69
PFE Sharpe Ratio Rank: 72
PFE Sortino Ratio Rank: 66
PFE Omega Ratio Rank: 63
PFE Calmar Ratio Rank: 72
PFE Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SKBSY vs. PFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Skanska AB ser. B ADR (SKBSY) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SKBSY	PFE	Difference
Sharpe ratio Return per unit of total volatility	1.21	0.94	+0.28
Sortino ratio Return per unit of downside risk	1.77	1.46	+0.30
Omega ratio Gain probability vs. loss probability	1.22	1.18	+0.04
Calmar ratio Return relative to maximum drawdown	2.00	1.66	+0.34
Martin ratio Return relative to average drawdown	6.48	3.73	+2.75
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SKBSY vs. PFE - Sharpe Ratio Comparison

The current SKBSY Sharpe Ratio is 1.21, which is comparable to the PFE Sharpe Ratio of 0.94. The chart below compares the historical Sharpe Ratios of SKBSY and PFE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SKBSY	PFE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.21	0.94	+0.28
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.16	0.01	+0.15
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.24	0.19	+0.05
Sharpe Ratio (All Time) Calculated using the full available price history	0.26	0.27	-0.01

Correlation

The correlation between SKBSY and PFE is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SKBSY vs. PFE - Dividend Comparison

SKBSY's dividend yield for the trailing twelve months is around 5.77%, less than PFE's 6.02% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
SKBSY Skanska AB ser. B ADR	5.77%	5.91%	2.50%	3.98%	6.64%	4.26%	3.94%	5.64%	6.58%	9.06%	7.79%	4.45%
PFE Pfizer Inc.	6.02%	6.91%	6.33%	5.70%	3.12%	2.64%	3.92%	3.68%	3.12%	3.53%	3.69%	3.47%

Drawdowns

SKBSY vs. PFE - Drawdown Comparison

The maximum SKBSY drawdown since its inception was -58.21%, roughly equal to the maximum PFE drawdown of -58.96%. Use the drawdown chart below to compare losses from any high point for SKBSY and PFE.

Drawdown Indicators

	SKBSY	PFE	Difference
Max Drawdown Largest peak-to-trough decline	-58.21%	-58.96%	+0.75%
Max Drawdown (1Y) Largest decline over 1 year	-18.67%	-12.59%	-6.08%
Max Drawdown (5Y) Largest decline over 5 years	-58.21%	-58.96%	+0.75%
Max Drawdown (10Y) Largest decline over 10 years	-58.21%	-58.96%	+0.75%
Current Drawdown Current decline from peak	-11.11%	-41.79%	+30.68%
Average Drawdown Average peak-to-trough decline	-17.20%	-17.33%	+0.13%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.75%	5.58%	+0.17%

Volatility

SKBSY vs. PFE - Volatility Comparison

Skanska AB ser. B ADR (SKBSY) has a higher volatility of 12.27% compared to Pfizer Inc. (PFE) at 6.30%. This indicates that SKBSY's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SKBSY	PFE	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.27%	6.30%	+5.97%
Volatility (6M) Calculated over the trailing 6-month period	20.87%	17.39%	+3.48%
Volatility (1Y) Calculated over the trailing 1-year period	29.60%	26.78%	+2.82%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	36.11%	25.47%	+10.64%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	35.22%	23.90%	+11.32%

Financials

SKBSY vs. PFE - Profitability Comparison

The chart below illustrates the profitability comparison between Skanska AB ser. B ADR and Pfizer Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

SKBSY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Skanska AB ser. B ADR reported a gross profit of 4.39B and revenue of 33.85B. Therefore, the gross margin over that period was 13.0%.

PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a gross profit of 12.29B and revenue of 17.56B. Therefore, the gross margin over that period was 70.0%.

SKBSY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Skanska AB ser. B ADR reported an operating income of 1.46B and revenue of 33.85B, resulting in an operating margin of 4.3%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported an operating income of 3.69B and revenue of 17.56B, resulting in an operating margin of 21.0%.

SKBSY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Skanska AB ser. B ADR reported a net income of 1.84B and revenue of 33.85B, resulting in a net margin of 5.4%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Pfizer Inc. reported a net income of -1.65B and revenue of 17.56B, resulting in a net margin of -9.4%.